Advancing science and implementing novel, cutting edge Technologies

StemBANCC aims to provide well characterised patient derived induced pluripotent stem cell lines and associated biomaterials in an accessible and sustainable bio-bank. StemBANCC also aims to demonstrate proof of concept for the utility of induced pluripotent stem cells in drug discovery for hard-to-treat disorders.

News & Events

ISSCR - Translational Opportunities in Stem Cell Research, 27 Feb - 1 March 2017


StemBANCC co-organised this international symposium where you could explore cutting-edge technology and the latest opportunities in stem cell research.


Click here to view the StemBANCC presentations at the ISSCR 2017.


CONCEPT: StemBANCC is a large-scale, five-year academic-industry partnership in the area of stem cell research. It brings together a consortium of 37 partners from pharmaceutical companies, research institutions and small and medium enterprises (SMEs) who collaborate and share their experience to exploit the rich expertise across sectors and enhance knowledge transfer between academia and industry for patient benefit.

MAIN OBJECTIVE: The main aim of the StemBANCC project is to generate and characterise high quality human induced pluripotent stem (iPS) cell lines to study a range of chronic diseases and test for drug efficacy and safety. The five major disease groups of interest are peripheral neuropathies, neurodegenerative disorders, neurodysfunctional disorders, diabetes and adverse drug responders.

Direct Links

 

 

Biomedicine West
International Centre for Life
Times Square
Newcastle upon Tyne
NE1 4EP
United Kingdom

 

www.newcellsbiotech.co.uk

 

Project leader

 
Dr. Mike Nicholds
CEO, team leader
E-Mail  

 


Company presentation

Newcells Biotech are experts in the production of induced pluripotent stem cells (iPSCs), their differentiation into a wide range of reliable and reproducible cell and tissue types and the development of cell-based assays.

Our focus is to provide customers engaged in drug discovery, pre-clinical development and disease mechanism investigation, with the best quality cells and services.

Company Background

Newcells Biotech, founded in 2014 as a spin out biotechnology company from Newcastle University, set out with the aim of providing innovative solutions to accelerate the drug discovery process in the pharmaceutical industry.

It was founded on the technology and expertise of one of the UK’s most experienced centres of stem cell biology based in Newcastle upon Tyne, UK. The team behind Newcells was one of the first to use iPSC (induced pluripotent stem cells) technology in the UK and is at the core of one of the main centres of reprogramming in Europe, which is on course to create 1,500 iPSC cell lines over the next 2.5 years.

Newcells is located close to one of the largest research-intensive medical university and hospital complexes in the UK giving us access to cell biologists and clinicians that understand cell differentiation and disease phenotypes

Our sources of disease-carrying patient's cells include collaborating clinicians and the Newcastle Biomedicine Biobank.

Newcells Biotech can source tissues from patients, generate iPSC from these, and convert the pluripotent cells into the somatic cell types required to model the disease. We have existing primary cell based assays for nephrotoxicity and transporter studies as well as assay development projects using iPSC technology for skin metabolism and retinal toxicity. We provide our services to drug discovery, toxicity and DMPK teams in Europe, USA and Japan.

 

INERIS (Institut National de l'Environnement Industriel et des Risques)
PARC ALATA, BP2
F-60550 Verneuil en Halatte
France

http://www.ineris.fr/

 

Project leader

 
Frederic Yves Bois
 
Phone +33 3 4455 6596
E-Mail  

 

Project staff

 
Lydia Boutigny
 
Phone +33 3 4461 8120
E-Mail  

Institute presentation

INERIS is a large public research institute whose mission is to provide scientific and technical assistance to the French Ministry for the Environment. With a staff of 600 persons, INERIS has extensive facilities and competence in toxicology in vitro, in vivo, and in silico. INERIS has experience in participating and managing large international research projects, including for the European Commission.

Within INERIS, the DRC/VIVA/METO (Models for Ecotoxicology and Toxicology) Unit, which includes 7 staff researchers, focuses its research activities on biomathematics, biostatistics and bioinformatics with applications to systems biology, quantitative in vitro to in vivo extrapolation, risk assessment, predictive toxicology and endocrine perturbation.

Coming soon after migration